Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

Eli Lilly topped first-quarter expectations and raised its sales outlook for 2022, prodding LLY stock to pop Thursday.

Investors Business Daily

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Investors Business Daily

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Will New Buys By The Best Mutual Funds Prop Up These Big-Name, But Pressured Stocks?

Making the latest list of new buys by the best mutual funds, Apple and GOOGL face headwinds, while Vertex and Lilly weather the storm.

Investors Business Daily

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility

GlaxoSmithKline's Covid treatment partner, Vir, will join the S&P SmallCap 600 next week, according to a report that sent Vir stock flying.

Investors Business Daily

As Eli Lilly Holds Above Breakout Level, Here Are Two Option Trade Ideas

The stock is trading above its 50-day and 200-day moving averages and those moving averages are sloping upward.

Investors Business Daily

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The

Benzinga

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Benzinga

Top Funds Pump Money Into Eli Lilly As It Nears Breakout With Rising Relative Strength

With Eli Lilly earning a spot on the list of new buys by top funds, LLY stock is setting up a new buy point as the market correction continues.

Investors Business Daily

Eli Lilly And 3 Other Stocks Sold By Insiders

Although US crude oil futures traded higher this morning, there were a few notable insider trades.

Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport

Eli Lilly And Co (NYSE: LLY)

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc (NASDAQ: IMGN) has

The Independent UK

US authorizes new antibody drug to fight omicron

U.S. health regulators have authorized a new antibody drug that targets the omicron variant

Benzinga

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

Benzinga

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Asharq Al-Awsat

US FDA Advisers Say More Data Needed for Cancer Drug Tested in China

A panel of outside advisers to the US Food and Drug Administration on Thursday voted to recommend that Innovent Biologics Inc and Eli Lilly and Co be required to conduct a trial of their lung cancer drug that is applicable to the US population. Data submitted to the FDA for…

The Independent UK

US buys 600K doses of new COVID antibody awaiting clearance

The Biden administration says it has purchased enough doses of a yet-to-be approved antibody drug to treat 600,000 patients with COVID-19

Benzinga

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Investors Business Daily

Lilly's Covid Antibodies Drove A Big Beat, But Omicron Will Limit Sales

Covid antibodies helped Eli Lilly score a fourth-quarter beat on Thursday, but Eli Lilly stock dipped on a cloudy future for those drugs.

Benzinga

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Eli Lilly And Co (NYSE: LLY)

Benzinga

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a

Benzinga

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

1 … 12 13 14 15

People

Joe Biden

64,509 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.